<img height="1" width="1" alt="" style="display:none" src="https://www.facebook.com/tr?ev=6019334797428&amp;cd[value]=0.00&amp;cd[currency]=USD&amp;noscript=1">
  • Value of 4Kscore
  • Elevated PSA Options for Prostate Cancer
  • How do I get the 4Kscore

Challenges of the PSA Test

PSA testing does not clearly distinguish between prostate cancer and less serious conditions. Read more.

The Solution: The 4Kscore Blood Test

The 4Kscore test provides a percent risk score that is your chance of having aggressive prostate cancer. Read more.


Who Needs the 4Kscore Test?

The 4Kscore Test is especially useful to help clarify the biopsy decision when you and your Urologist need more information to make a decision about whether or not to perform a prostate biopsy.


View the 4Kscore Patient Brochure


Learn how 4Kscore Test is helping clarify the biopsy decision.

How Does the 4Kscore Test Work?

Prostate cancer is the 2nd most deadly cancer afflicting men and estimated to kill more than 29,000 men in the US in 2014.  Urologists and primary care physicians currently screen men for prostate cancer using the PSA test and digital rectal exam (DRE). PSA screening, however, is not specific at identifying prostate cancer, and only about 20% of prostate biopsies performed following an elevated PSA reading find aggressive prostate cancer. That means that up to 80% of prostate biopsies are avoidable saving time, cost and discomfort for the patient and healthcare system. 

The 4Kscore Test is a blood test that delivers a patient-specific personalized risk score for having aggressive prostate cancer. The 4Kscore Test can help reduce the number of unnecessary biopsies, by providing information to improve decision making before ordering a prostate biopsy.



What are Medical Experts Saying About the 4Kscore Test?


“We're being told by many government bodies and regulatory agencies that we shouldn't even screen men for prostate cancer, yet we've seen the mortality rate for prostate cancer fall steadily over the last two decades with PSA screening. In my opinion, the response to the challenge we're facing in accurate detection of prostate cancer is not to abandon PSA testing altogether, but to learn how to test smarter, how to screen patients with PSA smarter and more accurately. I think the 4Kscore Test is a great tool for helping us do that.”

Peter Scardino, M.D. -FACS
Chairman, Department of Surgery
Memorial Sloan-Kettering Cancer Center



"The 4Kscore Test certainly addresses the controversies of prostate cancer screening, primarily by reducing the number of over diagnoses and indolent disease. It will also address the concerns of policy makers and others who question prostate cancer screening in general."

Dr. Daniel Lin
Professor and Chief of Urologic Oncology at the University of Washington



"The OPKO 4Kscore Test, the simple blood test with robust clinical markers, gives you very powerful information to then make a more accurate judgment."

Dipen Parekh, M.D.
Professor and Chair, Department of Urology, Director of Robotic Surgery, Dr. Victor A Politano Endowed Chair in Urology University of Miami Miller School of Medicine



"We as a country do about a million biopsies a year. Only 250,000 of those are positives."

John Libertino, M.D.
Chairman of the Institute of Urology, Lahey Clinic





“Prostate biopsy is a very anxiety-provoking procedure. Men are very fearful about one specific question: Do I have prostate cancer? The 4Kscore Test helps Urologists decide when a prostate biopsy is an appropriate next plan of action.”

Stephen Zappala, M.D.
Assistant Clinical Professor of Urology, Tufts University
Fellow-American College of Surgeons
Diplomat of the American Board of Urology



"The 4Kscore Test allows Urologists to do two things: one is to be much more selective about who they biopsy.  The second thing the 4Kscore Test allows you to do is have an informed decision with the patient about their risk of cancer. The 4Kscore Test gives you a percentage risk of cancer and you can then have a rational conversation with the patient about their preferences on what they want to do next.

Andrew Vickers, Ph.D.
Attending Research Methodologist
Memorial Sloan-Kettering Cancer Center